In the NeoSix project AnaMar is developing a new biomarker for diagnosing chronic joint disease as well as following joint disease activity. Currently very few biomarkers are commercially available for the monitoring of severity of joint destruction and prognosis in arthritic disease states - one of the few being AnaMar's own COMP® ELISA kit. The new NeoSix biomarker is developed as a complementary tool facilitating the diagnosis and clinical management of patients afflicted by erosive joint diseases.
